A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis.
10.4078/jrd.2014.21.5.274
- Author:
Min Jeong KIM
1
;
Ji Hyun LEE
;
Ho Joon IM
;
Hyun Jung YEO
;
Hong Jik LEE
;
Ki Sup BYUN
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, Korea. ete@lycos.co.kr
- Publication Type:Case Report
- Keywords:
Infliximab;
Psoriasis;
Ankylosing spondylitis
- MeSH:
Arthritis, Rheumatoid;
Crohn Disease;
Exanthema;
Korea;
Pruritus;
Psoriasis*;
Spondylitis, Ankylosing*;
Urticaria;
Infliximab
- From:Journal of Rheumatic Diseases
2014;21(5):274-277
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infliximab, which is indicated for refractory rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Crohn's disease, has cutaneous adverse events including skin rash, urticaria, pruritus, and lupus-like eruption. Psoriasis induced by infliximab is very rare. In Korea, it is infrequently reported in Crohn's disease or RA and never reported in AS. We encountered a case of psoriasis induced by infliximab treatment for AS, and report here on this case along with a review of the relevant literature.
